Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P830063/S031

Gambro Prismaflex TPE 2000 Set

Vantive US Healthcare, LLC · Decision date Dec 23, 2025

FDA DECISIONP830063/S031

What did the FDA decide?

FDA records P830063/S031 as a supplement to PMA P830063, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Dec 23, 2025.

FDA approval order statement

a new mold for the soft extension pierceable component of the Prismaflex TPE 2000 set
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Gastroenterology, Urology
Decision date
Dec 23, 2025
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P830063/S031
Regulatory pathway
PMA supplement
Product code
MDP
Decision code
OK30
Decision date
Dec 23, 2025
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Separator for therapeutic purposes, membrane automated blood cell/plasma.

Product code
MDP
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P830063/S031 received

    Application receipt date recorded by FDA.

  2. P830063/S031 · FDA decision

    30-Day Notice

Timeline entries are records held by MedtechLedger for P830063. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P830063

Product / regulatory recordCompanyPathwayDecision dateSource
Vantive US Healthcare, LLCPMA supplementMar 13, 2026FDA
Vantive US Healthcare, LLCPMA supplementJul 15, 2026FDA

Explore the linked device profile

Other records with product code MDP

Product / regulatory recordCompanyPathwayDecision dateSource
Asahi Kasei Medical Co., Ltd.PMA supplementApr 9, 2026FDA
Asahi Kasei Medical Co., Ltd.PMA supplementSep 30, 2025FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Vantive US Healthcare, LLC

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
510 Lake Cook Rd., Deerfield, IL, 60015

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records